Efficacy and long-term adverse effect pattern of lovastatin
- PMID: 3055921
- DOI: 10.1016/0002-9149(88)90004-5
Efficacy and long-term adverse effect pattern of lovastatin
Abstract
The efficacy of lovastatin, a potent inhibitor of HMG CoA reductase, has been established by numerous studies. At doses of 40 mg administered twice daily, lovastatin produces a mean reduction in total plasma cholesterol of 33%, attributable to a reduction in low-density lipoprotein cholesterol of 41%. The drug also produces a mean increase in high-density lipoprotein cholesterol of 9%, and a reduction in the high- and low-density lipoprotein cholesterol ratio of 44%. The serious reported adverse effects of lovastatin are myopathy (0.5%) and asymptomatic but marked and persistent increases in transaminases (1.9%). Both are reversible when therapy is discontinued. Myopathy has occurred mainly in patients with complicated histories who were receiving concomitant therapy with immunosuppressive drugs, gemfibrozil or niacin. In an ongoing long-term safety study, 744 patients have received lovastatin for an average duration of 2.5 years up to March 1988. Fifteen patients (2.0%) have been withdrawn because of drug-attributable adverse events: raised transaminases (9), skin rash (2), gastrointestinal symptoms (2), myopathy (1) and insomnia (1). No effect of the drug on the human lens has been observed up to the date mentioned above. Lovastatin has been available in the United States since September 1987. By March 1988, the drug had been prescribed for approximately 250,000 patients. This clinical experience has confirmed the tolerability observed in clinical trials. The good adverse-effect profile of lovastatin is thus now supported both by a substantial body of data in patients treated for over 2 years in clinical trials, and by experience in clinical use with a large number of patients since the drug has been available for prescription.
Similar articles
-
HMG CoA reductase inhibitors. Current clinical experience.Drugs. 1988;36 Suppl 3:83-6. doi: 10.2165/00003495-198800363-00017. Drugs. 1988. PMID: 3076126 Review.
-
Clinical experience with lovastatin.Am J Cardiol. 1990 Mar 20;65(12):23F-26F. doi: 10.1016/0002-9149(90)91251-z. Am J Cardiol. 1990. PMID: 2180268 Clinical Trial.
-
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.Ann Pharmacother. 1995 Jul-Aug;29(7-8):743-59. doi: 10.1177/106002809502907-818. Ann Pharmacother. 1995. PMID: 8520093 Review.
-
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up.Am J Cardiol. 1994 Oct 1;74(7):667-73. doi: 10.1016/0002-9149(94)90307-7. Am J Cardiol. 1994. PMID: 7942524 Clinical Trial.
-
Long-term clinical tolerance of lovastatin and simvastatin.Cardiology. 1990;77 Suppl 4:58-65. doi: 10.1159/000174684. Cardiology. 1990. PMID: 2073673 Review.
Cited by
-
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.Clin Pharmacokinet. 1997 May;32(5):403-25. doi: 10.2165/00003088-199732050-00005. Clin Pharmacokinet. 1997. PMID: 9160173 Review.
-
Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?Drugs Aging. 2008;25(8):649-64. doi: 10.2165/00002512-200825080-00003. Drugs Aging. 2008. PMID: 18665658 Review.
-
Statins-From Fungi to Pharmacy.Int J Mol Sci. 2023 Dec 29;25(1):466. doi: 10.3390/ijms25010466. Int J Mol Sci. 2023. PMID: 38203637 Free PMC article. Review.
-
Comparative tolerability of the HMG-CoA reductase inhibitors.Drug Saf. 2000 Sep;23(3):197-213. doi: 10.2165/00002018-200023030-00003. Drug Saf. 2000. PMID: 11005703 Review.
-
First Reported Case of Rhabdomyolysis Associated with Concomitant Use of Cyclosporin, Diltiazem, and Simvastatin.Indian J Nephrol. 2021 Mar-Apr;31(2):173-175. doi: 10.4103/ijn.IJN_5_20. Epub 2020 Nov 7. Indian J Nephrol. 2021. PMID: 34267441 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical